ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
August 14, 2024 16:05 ET
|
ReShape Lifesciences Inc
Entered into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Significant Reduction in Overall Operating Expenses of 45.4% in the First Half of 2024 Compared...
Draganfly Announces 30% Quarter Over Quarter Revenue Increase with Second Quarter Results for 2024
August 13, 2024 16:50 ET
|
Draganfly Inc
Vancouver, BC., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems...
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
August 09, 2024 07:30 ET
|
TenX Keane Acquisition
TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on...
Iterum Therapeutics Announces Expiration and Results of Rights Offering
August 06, 2024 17:30 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and...
Spartan Capital Securities, LLC and B2i Digital Announce the Spartan Capital Investor Conference 2024
August 05, 2024 09:00 ET
|
Spartan Capital Securities, LLC
Over 30 Companies to Present and Engage with Hundreds of Investors at the Iconic Pierre Hotel in New York City A Landmark Event Celebrating Spartan Capital’s 17 Years of Excellence in the Capital...
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
August 05, 2024 08:00 ET
|
TenX Keane Acquisition
TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on...
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
July 31, 2024 08:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
July 30, 2024 09:00 ET
|
Chemomab Therapeutics
Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026
OrangeKloud Technology Inc. Announces Closing of $13.1 Million Initial Public Offering
July 26, 2024 13:52 ET
|
Orangekloud Technology Inc.
SINGAPORE, July 26, 2024 (GLOBE NEWSWIRE) -- OrangeKloud Technology Inc. (“ORKT” or “the Company”) today announced the closing of its previously announced initial public offering of an aggregate...
Chemomab Therapeutics Announces $10 Million Private Placement
July 25, 2024 07:38 ET
|
Chemomab Therapeutics
Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.